Lilly Adds To Diabetes Pipeline With Protomer Buyout
Executive Summary
After investing in the California biotech, Lilly buys the company in search of safer insulin products. The pharma sees these candidates as pairing with tirzepatide to improve diabetes therapy overall.
You may also be interested in...
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Lilly Is Growing Its Next Crop Of Blockbusters
The pharma is digging deeper with early- and mid-stage R&D in age-related neurodegeneration, diabetes/obesity and other priority areas.
Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.